Estudio de la estructura factorial de la escala de calidad de vida FACIT-P para los pacientes con cáncer de próstata
Palabras clave:
Calidad de vida, neoplasias de la próstata, psicometría, cuestionariosResumen
Objetivo: Realizar el análisis de la estructura de dominios de la escala FACIT-P (4.a versión), instrumento diseñado para medir el constructo de calidad de vida en pacientes con cáncer de próstata (CP).
Métodos: El método seleccionado para delimitar las variables latentes fue el de máxima verosimilitud. La estructura factorial escogida para buscar variables latentes partió de una rotación ortogonal tipo varimax.
Resultados: En los pacientes evaluados, más de la mitad procedían de Bogotá, la gran mayoría solo había cursado primaria, y de acuerdo con la escala Gleason, una cuarta parte presentaba un CP de grado intermedio o alto. Los dominios incluidos fueron:
1. Aspectos que representan dolor y molestias.
2. Elementos relacionados con autonomía y capacidad de desempeño.
3. Aspectos de red social, familiar y satisfacción.
4. Elementos relacionados con depresión y ansiedad.
5. Síntomas específicos del cáncer de próstata.
Conclusiones: La estructura de dominios que muestra el instrumento en pacientes colombianos con CP mostró una organización de variables latentes plausible, y similares al constructo de la escala original.
Biografía del autor/a
Mónica Ballesteros, Instituto Nacional de Cancerología
Grupo Investigación Clínica, Instituto Nacional de Cancerología, Bogotá, D. C., Colombia
Ricardo Sánchez, Instituto Nacional de Cancerología
Grupo Investigación Clínica, Instituto Nacional de Cancerología, Bogotá, D. C., Colombia
Universidad Nacional de Colombia, Bogotá, D. C., Colombia
Bryan Merchán, Instituto Nacional de Cancerología
Grupo Investigación Clínica, Instituto Nacional de Cancerología, Bogotá, D. C., Colombia
Rodolfo Varela, Instituto Nacional de Cancerología
Grupo de Urología, Instituto Nacional de Cancerología, Bogotá, D. C., Colombia
Referencias bibliográficas
Leitzmann MF, Rohrmann S. Risk factors for the onset of prostatic cancer: age, location, and behavioral correlates. Clin Epidemiol. 2012;4:1-11.
https://doi.org/10.2147/CLEP.S16747
Maringe C, Mangtani P, Rachet B, Leon DA, Coleman MP, Dos Santos Silva I. Cancer incidence in South Asian migrants to England, 1986-2004: Unraveling ethnic from socioeconomic differentials. Int J Cancer. 2012. Epub 2012/09/11.
https://doi.org/10.1002/ijc.27826
Outzen M, Brasso K, Martinussen N, Christensen J, Tjonneland A, Friis S, et al. Prostate cancer in Denmark 1978-2009 - trends in incidence and mortality. Acta Oncol. 2012. Epub 2012/07/20.
https://doi.org/10.3109/0284186X.2012.702922
Shafique K, Oliphant R, Morrison DS. The impact of socio-economic circumstances on overall and grade-specific prostate cancer incidence: a population-based study. Br J Cancer. 2012;107:575-82.
https://doi.org/10.1038/bjc.2012.289
Scosyrev E, Wu G, Mohile S, Messing EM. Prostate-specific antigen screening for prostate cancer and the risk of overt metastatic disease at presentation : Analysis of trends over time. Cancer. 2012. Epub 2012/08/01.
https://doi.org/10.1002/cncr.27503
Ferlay J, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v2.0. Lyon, France [internet]. 2008 [citado: 17 de junio de 2011]. Disponible en: http://globocan.iarc.fr.
Piñeros M, Ferlay J, Murillo R. Incidencia estimada y mortalidad por cáncer en Colombia: 1995-1999. Bogotá: Imprenta Nacional; 2005.
Hunt SM. Cross-cultural comparability of quality of life measures. Drug Inf J. 1993;27:395-400.
https://doi.org/10.1177/009286159302700223
O'Rourke ME. Choose wisely: therapeutic decisions and quality of life in patients with prostate cancer. Clin J Oncol Nurs. 2007;11:401-8.
https://doi.org/10.1188/07.CJON.401-408
Esper P, Mo F, Chodak G, Sinner M, Cella D, Pienta KJ. Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology. 1997;50:920-8.
https://doi.org/10.1016/S0090-4295(97)00459-7
Batista-Miranda JE, Sevilla-Cecilia C, Torrubia R, Musquera M, Huguet-Perez J, Ponce de Leon X, et al. Quality of life in prostate cancer patients and controls: psychometric validation of the FACTP-4 in Spanish, and relation to urinary symptoms. Arch Españ Urol. 2003;56:447-54.
Hong JH, Jeon SS, Lee HM, Choi YH, Kim S, Choi HY. The Functional Assessment of Cancer Therapy-Prostate (FACTP) scales in men with prostate cancer: reliability and validity of the Korean version. J Kor Med Sci. 2006;21:295-9.
https://doi.org/10.3346/jkms.2006.21.2.295
Webster K, Cella D, Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation. Health Qual Life Out. 2003;1:79.
https://doi.org/10.1186/1477-7525-1-79
Haseen F, Murray LJ, O'Neill RF, O'Sullivan JM, Cantwell MM. A randomised controlled trial to evaluate the efficacy of a 6 month dietary and physical activity intervention for prostate cancer patients receiving androgen deprivation therapy. Trials. 2010;11:86.
https://doi.org/10.1186/1745-6215-11-86
Nelson CJ, Weinberger MI, Balk E, Holland J, Breitbart W, Roth AJ. The chronology of distress, anxiety, and depression in older prostate cancer patients. Oncologist. 2009;14:891-9.
https://doi.org/10.1634/theoncologist.2009-0059
Sia M, Rodríguez G, Menard C, Bayley A, Bristow R, Chung P, et al. Treatment-related toxicity and symptom-related bother following postoperative radiotherapy for prostate cancer. Can Urol Assoc J. 2010;4:105-11.
https://doi.org/10.5489/cuaj.801
Syndikus I, Morgan RC, Sydes MR, Graham JD, Dearnaley DP. Late gastrointestinal toxicity after dose-escalated conformal radiotherapy for early prostate cancer: results from the UK Medical Research Council RT01 trial (ISRCTN47772397). Int J Rad Oncol. 2010;77:773-83.
https://doi.org/10.1016/j.ijrobp.2009.05.052
Warde P, Mason M, Ding K, Kirkbride P, Brundage M, Cowan R, et al. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet. 2011;378:2104-11.
https://doi.org/10.1016/S0140-6736(11)61095-7
Litwin MS, Hays RD, Fink A, Ganz PA, Leake B, Brook RH. The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure. Med Care. 1998;36:1002-12.
https://doi.org/10.1097/00005650-199807000-00007
Stockler MR, Osoba D, Goodwin P, Corey P, Tannock IF. Responsiveness to change in health-related quality of life in a randomized clinical trial: a comparison of the Prostate Cancer Specific Quality of Life Instrument (PROSQOLI) with analogous scales from the EORTC QLQ-C30 and a trial specific module. European Organization for Research and Treatment of Cancer. J Clin Epidemiol. 1998;51:137-45.
https://doi.org/10.1016/S0895-4356(97)00269-2
Van Andel G, Bottomley A, Fossa SD, Efficace F, Coens C, Guerif S, et al. An international field study of the EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer. Eur J Cancer. 2008;44:2418-24.
https://doi.org/10.1016/j.ejca.2008.07.030
Rosner B. Fundamentals of Biostatistics. 7th ed. Boston: Cengage Learning; 2011.
Pett MA, Lackey NR, Sullivan JJ. Making sense of factor analysis. The use of factor analysis for instrument development in health care research. Thousand Oaks, Calif: Sage Pub; 2003.
https://doi.org/10.4135/9781412984898
Kaiser HF. The varimax criterion for analytic rotation in factor análisis. Psychometrika. 1958;23:187-200.
https://doi.org/10.1007/BF02289233
Fitzpatrick JM, Graefen M, Payne HA, Scotte F, Aapro MS. A comment on the international society of geriatric oncology guidelines: evidence-based advice for the clinical setting. Oncologist. 2012;17(Suppl 1):31-5.
https://doi.org/10.1634/theoncologist.2012-S1-31
Hellerstedt B, Pienta KJ, Redman BG, Esper P, Dunn R, Fardig J, et al. Phase II trial of oral cyclophosphamide, prednisone, and diethylstilbestrol for androgen-independent prostate carcinoma. Cancer. 2003;98:1603-10.
Cómo citar
Descargas
Descargas
Publicado
Número
Sección
Licencia
Todos los derechos reservados.
